Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

968 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Response to: Letter to the Editor Regarding "Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-analysis".
Ismaila AS, Haeussler K, Malmenäs M, Sharma R, Compton C, Vogelmeier CF, Han MK, Halpin DMG. Ismaila AS, et al. Among authors: han mk. Adv Ther. 2023 May;40(5):2556-2561. doi: 10.1007/s12325-023-02495-0. Epub 2023 Apr 1. Adv Ther. 2023. PMID: 37004642 Free PMC article. No abstract available.
Mortality risk reduction with budesonide/glycopyrrolate/formoterol fumarate versus fluticasone furoate/umeclidinium/vilanterol in COPD: a matching-adjusted indirect comparison based on ETHOS and IMPACT.
Stolz D, Hermansson E, Ouwens M, Singh B, Sharma A, Jackson D, Darken P, Marshall J, Bowen K, Müllerová H, Alcázar Navarrete B, Russell R, Han MK, Tansey-Dwyer D. Stolz D, et al. Among authors: han mk. Curr Med Res Opin. 2023 Oct;39(10):1395-1405. doi: 10.1080/03007995.2023.2247969. Epub 2023 Aug 29. Curr Med Res Opin. 2023. PMID: 37583267 Free article.
COPD in Women: Future Challenges.
Scicluna V, Han M. Scicluna V, et al. Arch Bronconeumol. 2023 Jan;59(1):3-4. doi: 10.1016/j.arbres.2022.06.008. Epub 2022 Jul 7. Arch Bronconeumol. 2023. PMID: 35902294 Free PMC article. No abstract available.
Impact of the CAPTURE COPD Screening Tool in US Primary Care: A Cluster Randomized Trial.
Martinez FJ, Yawn BP, Angulo D, Lopez C, Murray S, Mannino D, Anderson S, Dolor R, Elder N, Joo M, Khan I, Knox LM, Meldrum C, Peters E, Spino C, Tapp H, Thomashow B, Zittleman L, Brown R, Make B, Han MK; CAPTURE study group. Martinez FJ, et al. Among authors: han mk. Am J Respir Crit Care Med. 2024 Dec 23. doi: 10.1164/rccm.202405-0921OC. Online ahead of print. Am J Respir Crit Care Med. 2024. PMID: 39715575
Preserved Ratio Impaired Spirometry in US Primary Care Patients Diagnosed with Chronic Obstructive Pulmonary Disease.
Evans A, Tarabichi Y, Pace WD, Make B, Bushell N, Carter V, Chang KL, Fox C, Han MK, Kaplan A, Kocks JWH, Le Lievre C, Roussos A, Skolnik N, Soriano JB, Yawn BP, Price D. Evans A, et al. Among authors: han mk. Pragmat Obs Res. 2024 Dec 13;15:221-232. doi: 10.2147/POR.S478721. eCollection 2024. Pragmat Obs Res. 2024. PMID: 39691636 Free PMC article.
Is Disease Stability an Attainable COPD Treatment Goal?
Singh D, Han MK, Bhatt SP, Miravitlles M, Compton C, Kolterer S, Mohan T, Sreedharan SK, Tombs L, Halpin DMG. Singh D, et al. Among authors: han mk. Am J Respir Crit Care Med. 2024 Dec 16. doi: 10.1164/rccm.202406-1254CI. Online ahead of print. Am J Respir Crit Care Med. 2024. PMID: 39680953
Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe chronic obstructive pulmonary disease (COURSE): a randomised, placebo-controlled, phase 2a trial.
Singh D, Brightling CE, Rabe KF, Han MK, Christenson SA, Drummond MB, Papi A, Pavord ID, Molfino NA, Almqvist G, Kotalik A, Hellqvist Å, Gołąbek M, Sindhwani NS, Ponnarambil SS; COURSE study investigators. Singh D, et al. Among authors: han mk. Lancet Respir Med. 2025 Jan;13(1):47-58. doi: 10.1016/S2213-2600(24)00324-2. Epub 2024 Dec 6. Lancet Respir Med. 2025. PMID: 39653044 Clinical Trial.
GOLD Science Committee recommendations for the use of pre- and post-bronchodilator spirometry for the diagnosis of COPD.
Singh D, Stockley R, Anzueto A, Agusti A, Bourbeau J, Celli BR, Criner GJ, Han MK, Martinez FJ, Montes de Oca M, Ozoh OB, Papi A, Pavord I, Roche N, Salvi S, Sin DD, Troosters T, Wedzicha J, Zheng J, Volgelmeier C, Halpin D. Singh D, et al. Among authors: han mk. Eur Respir J. 2024 Dec 5:2401603. doi: 10.1183/13993003.01603-2024. Online ahead of print. Eur Respir J. 2024. PMID: 39638416
Associations between life-course FEV1/FVC trajectories and respiratory symptoms up to middle age: analysis of data from two prospective cohort studies.
Perret JL, Bui DS, Pistenmaa C, Vicendese D, Khan SS, Han MK, San José Estépar R, Lowe AJ, Lodge CJ, Labaki WW, Pham JV, Idrose NS, Senaratna CV, Tan DJ, Hamilton GS, Thompson BR, Munsif M, Arynchyn A, Jacobs DR Jr, Abramson MJ, Walters EH, Washko GR, Kalhan R, Dharmage SC; AUSCULTATE investigator group. Perret JL, et al. Among authors: han mk. Lancet Respir Med. 2024 Nov 27:S2213-2600(24)00265-0. doi: 10.1016/S2213-2600(24)00265-0. Online ahead of print. Lancet Respir Med. 2024. PMID: 39615504
968 results